Study identifier:D7260C00010
ClinicalTrials.gov identifier:NCT06857695
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-Label Study to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5004 and Absolute Bioavailability of AZD5004 in Healthy Male Participants
Healthy Participants
Phase 1
Yes
AZD5004 film-coated tablet, [14C]AZD5004 Solution for Infusion, [14C]AZD5004 Oral Solution
Male
8
Interventional
30 Years - 65 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Mar 2025 by AstraZeneca
AstraZeneca
Quotient Sciences Limited
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD5004 A single dose of AZD5004 film-coated tablet and a single dose of [14C]AZD5004 Solution for Infusion (Part 1) A single dose of [14C]AZD5004 Oral Solution (Part 2) | - |